Amylyx price target lowered to $42 from $50 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Amylyx to $42 from $50 and keeps a Buy rating on the shares. Based on the number of patients staying on Relyvrio, the firm revisited revenue assumptions by lowering its overall penetration rates to reflect a high level of discontinuation.